ifta-2 Antibody

What is IFTA-2 and why is it important in research?

IFTA-2 is a conserved cilia protein involved in pathways regulating longevity. It localizes to cilia and moves along the cilia axoneme similar to other intraflagellar transport (IFT) proteins. Unlike other IFT genes, disruption of ifta-2 does not result in overt cilia assembly abnormalities, suggesting it plays a more specialized role in cilia function . Research has demonstrated that IFTA-2 significantly influences lifespan in C. elegans, as ifta-2(tm1724) mutants exhibit increased longevity compared to wild-type controls .

The protein's significance stems from its unique position at the intersection of cilia biology and longevity regulation. IFTA-2 appears to function within the DAF-2 signaling pathway, as demonstrated by epistasis experiments showing that daf-2(e1370);ifta-2(tm1724) double mutants do not display additive effects on lifespan compared to single mutants . Additionally, IFTA-2's homology with Rab proteins suggests a potential role in regulating protein transport within cilia, making it an intriguing target for studies connecting ciliary function to aging processes.

What experimental methods are most effective for detecting IFTA-2 using antibodies?

For effective IFTA-2 detection using antibodies, researchers should consider several methodological approaches:

• Immunofluorescence microscopy: This technique is particularly valuable for visualizing IFTA-2 localization within cilia. The search results indicate that IFTA-2 concentrates in cilia in a pattern similar to DAF-2 and AGE-1 . When performing immunofluorescence, it's crucial to:

  • Use appropriate fixation methods that preserve ciliary structures

  • Include co-staining with established ciliary markers

  • Compare staining patterns in wild-type and ifta-2 mutant samples as specificity controls

• Western blotting: For quantitative analysis of IFTA-2 expression levels, western blotting with optimized protein extraction methods specific for ciliary proteins is recommended.

• Immunoprecipitation: To investigate IFTA-2 interaction partners, immunoprecipitation coupled with mass spectrometry can reveal novel protein associations.

• Live-cell imaging: For dynamic studies, combining antibody fragments with live-cell imaging techniques can track IFTA-2 movement along cilia in real-time.

The availability of ifta-2 deletion mutants (tm1724 and tm1725) provides excellent negative controls for validating antibody specificity across these methods .

How do IFTA-2 antibodies contribute to understanding cilia function in model organisms?

IFTA-2 antibodies provide valuable tools for elucidating cilia function across various model organisms through several research applications:

• Comparative localization studies: Antibodies allow researchers to map IFTA-2 distribution within cilia across different tissues and developmental stages. This helps establish whether IFTA-2 has tissue-specific functions within cilia.

• Genetic interaction analysis: In combination with genetic mutants, IFTA-2 antibodies enable researchers to determine how various genetic backgrounds affect IFTA-2 localization and expression. For example, studies in C. elegans have used IFTA-2::GFP transgenic lines to assess rescue of the longevity phenotype in ifta-2(tm1724) mutants .

• Protein interaction networks: By using IFTA-2 antibodies for co-immunoprecipitation studies, researchers can identify interaction partners within the cilium, potentially revealing functional complexes.

• Signal transduction pathway mapping: IFTA-2 antibodies have helped establish connections between cilia and longevity pathways. Research shows that loss of ifta-2 alters DAF-16 localization similar to loss of daf-2, supporting genetic evidence that ifta-2 functions in the DAF-2–DAF-16 pathway .

• Evolutionary conservation assessment: Using antibodies against conserved IFTA-2 epitopes across species helps determine the evolutionary conservation of IFTA-2 function in cilia biology.

How can IFTA-2 antibodies help resolve the relationship between cilia, IFTA-2, and longevity regulation?

IFTA-2 antibodies provide sophisticated tools for investigating the complex relationship between ciliary function and lifespan regulation through several methodological approaches:

• Subcellular co-localization analysis: IFTA-2 antibodies enable precise mapping of IFTA-2's spatial relationship with components of the DAF-2 pathway. Research has shown that both DAF-2 and AGE-1 are concentrated in cilia in a pattern similar to IFTA-2, suggesting functional relationships . By using high-resolution imaging with IFTA-2 antibodies, researchers can determine whether these proteins exist in the same protein complexes or merely share the same subcellular compartment.

• Age-dependent expression profiling: By analyzing IFTA-2 expression and localization across different ages using antibodies, researchers can determine whether its dynamics change during aging. This addresses whether IFTA-2's role in longevity is related to age-dependent changes in its expression or function.

• Stimulus-response tracking: IFTA-2 antibodies allow researchers to track how IFTA-2 localization and expression respond to interventions that alter lifespan, such as dietary restriction or stress exposure. This helps establish whether IFTA-2 is a mediator or marker of longevity pathways.

• DAF-16 nuclear translocation studies: Research has demonstrated that loss of ifta-2 increases DAF-16 nuclear localization . Using IFTA-2 antibodies in combination with DAF-16 antibodies in time-course experiments can reveal the temporal relationship between IFTA-2 activity and DAF-16 nuclear accumulation.

• Cross-species comparative analysis: By applying IFTA-2 antibodies across evolutionarily diverse model organisms, researchers can determine whether the connection between IFTA-2, cilia, and longevity is evolutionarily conserved.

What methodological considerations are important when using IFTA-2 antibodies for investigating protein-protein interactions?

When using IFTA-2 antibodies to study protein-protein interactions, researchers should consider several methodological factors for optimal results:

• Preservation of native complexes: IFTA-2's homology with Rab proteins suggests it may form dynamic, potentially transient interactions . Consider using chemical crosslinking prior to cell lysis to stabilize these interactions.

• Detergent selection: The ciliary localization of IFTA-2 requires careful selection of detergents that solubilize membrane-associated proteins while preserving protein-protein interactions. A comparative analysis of different detergents (e.g., CHAPS, Brij-35, digitonin) should be performed to determine optimal extraction conditions.

• Buffer optimization: For co-immunoprecipitation of IFTA-2 and its partners, buffer conditions should be optimized to maintain physiological interactions. Consider variables including:

  Buffer Component	Recommended Range	Rationale
  pH	7.2-7.6	Maintains physiological conditions
  Salt (NaCl)	100-150 mM	Reduces non-specific interactions without disrupting specific ones
  Divalent cations	1-5 mM Mg²⁺/Ca²⁺	May stabilize certain protein interactions
  Protease inhibitors	Complete cocktail	Prevents degradation during processing

• Validation with reverse immunoprecipitation: When IFTA-2 antibodies identify a potential interaction partner, confirm the interaction by performing reverse immunoprecipitation using antibodies against the partner protein.

• Proximity labeling alternatives: Consider supplementing traditional co-immunoprecipitation with proximity labeling approaches (BioID, APEX) using IFTA-2 as bait to capture transient or weak interactions that might be lost during conventional immunoprecipitation.

• Functional validation: After identifying interaction partners using IFTA-2 antibodies, validate the functional significance through genetic interaction studies or analysis in ifta-2 mutant backgrounds .

How can researchers use IFTA-2 antibodies to investigate the paradox between its structural homology to transport proteins and its functional role in longevity?

IFTA-2 presents an interesting paradox: it shares structural homology with Rab proteins involved in vesicular transport, yet functionally influences longevity through the DAF-2–DAF-16 pathway . IFTA-2 antibodies offer several methodological approaches to investigate this paradox:

• Domain-specific antibody mapping: Generate and characterize antibodies targeting different domains of IFTA-2, particularly comparing regions shared with Rab proteins versus unique regions. This approach can reveal which structural elements correlate with which functions.

• Conformational state analysis: If IFTA-2 cycles between active and inactive states like Rab proteins, conformational-specific antibodies can help determine whether different configurations correlate with different functions.

• Trafficking studies: Use IFTA-2 antibodies to track its movement within cilia and determine whether it transports specific cargo proteins related to the DAF-2 pathway. Research has shown that IFTA-2 is not required for the ciliary targeting of DAF-2 or AGE-1 , but it may transport other signaling components.

• Comparative analysis with IFT mutants: The research data show that osm-5(m184);ifta-2(tm1724) double mutants have a lifespan not significantly different from ifta-2(tm1724) single mutants but longer than osm-5(m184) alone . Using IFTA-2 antibodies to analyze protein localization and interactions in these genetic backgrounds can help distinguish between IFTA-2's transport-related and longevity-related functions.

• Post-translational modification mapping: Generate modification-specific antibodies to determine whether IFTA-2 undergoes post-translational modifications that might switch it between transport and signaling functions.

This multi-faceted approach can help determine whether IFTA-2's dual nature represents true moonlighting functions or indicates a mechanistic link between vesicular transport and longevity regulation.

What validation steps are essential for confirming IFTA-2 antibody specificity?

Rigorous validation of IFTA-2 antibodies is crucial for generating reliable research data. Researchers should implement the following comprehensive validation protocol:

• Genetic validation: Test antibodies on samples from wild-type organisms and ifta-2 deletion mutants. The search results describe two independent deletion mutants, FX1724 ifta-2(tm1724) and FX1725 ifta-2(tm1725), which provide excellent negative controls . A specific antibody should show signal in wild-type samples but not in these deletion mutants.

• Recombinant protein controls: Validate antibody recognition of purified recombinant IFTA-2 protein through western blotting and ELISA to confirm target specificity and determine optimal working concentrations.

• Peptide competition assays: Pre-incubate the antibody with excess purified IFTA-2 protein or the immunizing peptide before application in experimental procedures. This should eliminate specific staining while leaving non-specific signals unchanged.

• Cross-species reactivity assessment: If using the antibody across multiple model organisms, validate specificity in each species separately, as epitope conservation may vary.

• Correlation with genetic reporter: Compare antibody staining patterns with IFTA-2::GFP localization in transgenic lines. The search results mention IFTA-2::GFP transgenic strains used for rescue experiments , which provide excellent tools for antibody validation.

• Multiple antibody concordance: When possible, compare results using antibodies raised against different epitopes of IFTA-2. Concordant results from independent antibodies strongly support specificity.

• Mass spectrometry verification: Perform immunoprecipitation followed by mass spectrometry to confirm the antibody captures IFTA-2 and to identify any cross-reacting proteins.

How can researchers optimize detection sensitivity for low-abundance IFTA-2 in different experimental contexts?

Detecting low-abundance IFTA-2 requires optimization strategies tailored to specific experimental techniques:

• Immunofluorescence enhancement strategies:

  • Signal amplification: Implement tyramide signal amplification (TSA) or quantum dot labeling to enhance detection sensitivity by 10-100 fold.

  • Optimized fixation: Compare paraformaldehyde, methanol, and glutaraldehyde fixation to determine which best preserves IFTA-2 epitopes.

  • Background reduction: Use appropriate blocking agents (BSA, normal serum, commercial blockers) and optimize antibody dilutions to improve signal-to-noise ratio.

  • Super-resolution microscopy: Employ STORM, PALM, or STED microscopy to detect low-abundance IFTA-2 in subciliary compartments.

• Western blot sensitivity enhancement:

  • Extraction optimization: Test specialized lysis buffers designed for ciliary proteins to maximize IFTA-2 recovery.

  • Concentration methods: Use immunoprecipitation to concentrate IFTA-2 before western blotting.

  • Detection systems: Employ high-sensitivity chemiluminescent substrates or fluorescent secondary antibodies with digital imaging.

• Immunoprecipitation refinement:

  • Bead selection: Compare magnetic, agarose, and sepharose beads to identify optimal binding conditions.

  • Pre-clearing optimization: Thoroughly pre-clear lysates to reduce non-specific binding.

  • Elution conditions: Test various elution strategies to maximize recovery of intact IFTA-2 complexes.

• Quantitative considerations:

  • Standard curves: Generate standard curves using recombinant IFTA-2 to enable absolute quantification.

  • Internal controls: Include appropriate loading controls, especially those specific to ciliary compartments.

These optimization strategies should be systematically tested and documented to establish reproducible protocols for detecting IFTA-2 across experimental contexts.

How do antibodies against IFTA-2 compare with antibodies against other IFT proteins for studying cilia biology?

Antibodies against IFTA-2 offer distinct advantages and limitations compared to antibodies against other intraflagellar transport (IFT) proteins:

Methodological implications for researchers:

• For studies examining basic cilia structure and formation, antibodies against canonical IFT proteins may provide more informative results than IFTA-2 antibodies.

• For investigations connecting cilia to longevity pathways, IFTA-2 antibodies offer unique advantages not provided by other IFT protein antibodies.

• Combining IFTA-2 antibodies with antibodies against other IFT proteins in multiplexed imaging can reveal functional specialization within the ciliary transport machinery.

• When studying genetic interaction networks, IFTA-2 antibodies enable distinct experimental designs focused on aging pathways rather than ciliary assembly.

• For pharmacological studies targeting cilia-related diseases, IFTA-2 antibodies may help distinguish between compounds affecting basic ciliary structure versus specialized functions.

What research questions about IFTA-2 remain unresolved due to limitations in current antibody technology?

Despite advances in antibody technology, several important research questions about IFTA-2 remain challenging to address:

• Conformational state detection: If IFTA-2 cycles between active and inactive states (similar to Rab proteins), current antibodies may not distinguish between these conformational states. This limitation hampers understanding of IFTA-2's activation cycle and regulation.

• Dynamic interaction mapping: Standard antibody-based approaches provide limited temporal resolution for tracking the rapid movement of IFTA-2 along cilia axonemes . This restricts our ability to understand the dynamics of IFTA-2's interactions during ciliary transport.

• Post-translational modification profiling: Current antibodies typically recognize IFTA-2 regardless of its modification state, making it difficult to determine how post-translational modifications might regulate IFTA-2's dual roles in transport and longevity pathways.

• Subciliary compartment resolution: While IFTA-2 is known to localize to cilia , current antibody-based imaging may lack the resolution to precisely map IFTA-2 distribution within ciliary subdomains, limiting understanding of its compartmentalization.

• Tissue-specific variant detection: If IFTA-2 has tissue-specific isoforms, current antibodies may not distinguish between them, obscuring potential tissue-specific functions.

Methodological solutions for future research:

• Development of conformation-specific antibodies using new computational design approaches like RFdiffusion

• Integration of antibody-based detection with emerging spatial transcriptomics and proteomics methods

• Generation of modification-specific antibodies targeting known or predicted IFTA-2 post-translational modifications

• Application of super-resolution microscopy with specialized antibody formats for improved spatial resolution

• Development of isoform-specific antibodies based on unique epitopes in variant regions

How can IFTA-2 antibodies contribute to understanding the relationship between cilia dysfunction and kidney pathologies?

The search results reveal an intriguing connection between IFTA-2 (a cilia protein) and IFTA (Interstitial Fibrosis and Tubular Atrophy) in kidney pathology. Although these are distinct entities, cilia dysfunction is increasingly recognized as contributing to kidney diseases. IFTA-2 antibodies offer valuable tools for investigating this relationship:

• Comparative expression analysis: Using IFTA-2 antibodies to compare expression patterns in normal kidney tissue versus kidney tissue with IFTA pathology could reveal whether alterations in this cilia protein correlate with fibrotic changes. Research shows that IFTA is found in approximately 25% of 1-year biopsies post-transplantation , providing clinical samples for such comparisons.

• Biomarker development: IFTA-2 antibodies could be used to develop diagnostic assays to detect IFTA-2 in urine or blood, potentially serving as biomarkers for early detection of kidney diseases associated with cilia dysfunction or for monitoring transplant rejection.

• Mechanistic studies: In experimental models of kidney injury, IFTA-2 antibodies can determine whether changes in IFTA-2 expression or localization precede, coincide with, or follow the development of interstitial fibrosis and tubular atrophy. This temporal relationship would help establish whether IFTA-2 dysregulation contributes to or results from kidney damage.

• Therapeutic target validation: If IFTA-2 plays a role in kidney disease progression, therapeutic antibodies targeting IFTA-2 could be developed and tested in preclinical models to determine whether modulating its function affects disease outcomes.

• Gene expression correlation: Research indicates that IFTA samples show dysregulated gene expression profiles similar to those seen in acute rejection (AR) biopsies . IFTA-2 antibodies could help determine whether changes in this protein correlate with these gene expression patterns.

This research direction could provide valuable insights linking ciliary biology to kidney pathology while potentially identifying new diagnostic and therapeutic approaches.

How can modern antibody design technologies like RFdiffusion advance IFTA-2 research?

Recent advances in AI-driven antibody design, specifically RFdiffusion technology , offer transformative opportunities for IFTA-2 research:

• Epitope-specific targeting: RFdiffusion can design antibodies that precisely target specific functional domains of IFTA-2, such as:

  • Regions homologous to Rab proteins

  • Domains involved in DAF-2–DAF-16 pathway interactions

  • Ciliary localization signals

• Conformation-selective antibodies: If IFTA-2 adopts different conformations during its transport and signaling functions, RFdiffusion could generate antibodies that selectively recognize each state, providing unprecedented insights into IFTA-2's activation cycle.

• Single-chain variable fragments (scFvs): The research results indicate that RFdiffusion has been trained to generate human-like antibodies in scFv format . These smaller antibody fragments offer advantages for IFTA-2 research, including:

  • Better penetration into ciliary compartments

  • Improved access to sterically hindered epitopes

  • Compatibility with intracellular expression for live-cell tracking

• Species cross-reactivity engineering: RFdiffusion could design antibodies that recognize conserved epitopes across species, facilitating comparative studies of IFTA-2 function in different model organisms while reducing the need for species-specific antibody development.

• Therapeutic development potential: As connections between IFTA-2, cilia function, and disease emerge, RFdiffusion could accelerate the development of therapeutic antibodies targeting IFTA-2 for conditions related to ciliary dysfunction.

The search results indicate that RFdiffusion has already been validated for designing antibodies against disease-relevant targets , suggesting its readiness for application to IFTA-2 research.

What role might IFTA-2 antibodies play in connecting research on ciliopathies with research on aging-related diseases?

IFTA-2 antibodies offer unique tools for investigating the emerging connections between ciliary dysfunction (ciliopathies) and aging-related pathologies:

• Comparative tissue analysis: The search results demonstrate that ifta-2 mutants display increased lifespan , suggesting IFTA-2 may link ciliary function to aging processes. IFTA-2 antibodies enable systematic comparison of IFTA-2 expression and localization across tissues in:

  • Young versus aged organisms

  • Normal versus ciliopathy models

  • Normal versus age-related disease models

• Signaling pathway integration: IFTA-2 antibodies can help map how ciliary signaling intersects with known longevity pathways. Research shows that IFTA-2 influences the DAF-2–DAF-16 pathway , which regulates lifespan. By using IFTA-2 antibodies in combination with antibodies against components of other aging-related pathways (mTOR, AMPK, sirtuins), researchers can build comprehensive interaction maps.

• Intervention response monitoring: When testing interventions that extend lifespan or improve ciliary function, IFTA-2 antibodies provide molecular readouts to assess mechanism of action. These could include:

  • Changes in IFTA-2 expression levels

  • Alterations in ciliary localization

  • Modified interaction with binding partners

  • Post-translational modification changes

• Multi-omics integration: Combining IFTA-2 antibody-based studies with other omics approaches can reveal broader patterns. For example, correlating IFTA-2 immunoprecipitation data with transcriptomic changes in aging or ciliopathy models could identify downstream effectors.

• Biomarker development: IFTA-2 antibodies could help develop diagnostic tools to identify individuals at risk for both ciliopathies and accelerated aging, potentially enabling earlier intervention.

This research direction holds promise for identifying shared molecular mechanisms underlying seemingly distinct disease categories and could lead to novel therapeutic strategies targeting both ciliopathies and age-related conditions.